The nordic prescription databases as a resource for pharmacoepidemiological research-a literature review

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 7, 2013, Pages 691-699

  Wettermark, B ^a,b   Zoega H ^c,d   Furu, K ^e,f   Korhonen, M ^g   Hallas, J ^h   Norgaard M ⁱ   Almarsdottir, Ab ^c,h   Andersen, M ^a,b,h   Andersson Sundell, K ^j   Bergman, U ^a,b   Helin Salmivaara, A ^k   Hoffmann, M ^l   Kieler, H ^a   Martikainen, Je ^m   Mortensen, M ⁱ   Petzold, M ⁿ   Wallach Kildemoes, H ^o   Wallin, C ^a   Sorensen H ⁱ  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ICELAND   (Iceland)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

^g UNIVERSITY OF TURKU   (Finland)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^k HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^l Network for Pharmacoepidemiology Foundation   (Sweden)

^m SOCIAL INSURANCE INSTITUTION   (Finland)

ⁿ UNIVERSITY OF GOTHENBURG   (Sweden)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Cross national comparison; Drug utilization; Effectiveness; Observational studies; Pharmacoepidemiology; Prescription databases; Record linkage; Safety

Indexed keywords

CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; GASTROINTESTINAL AGENT; HORMONE;

DENMARK; DRUG SAFETY; DRUG UTILIZATION; FINLAND; HUMAN; ICELAND; MEDLINE; NORWAY; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCREENING; SWEDEN;

CROSS-NATIONAL COMPARISON; DRUG UTILIZATION; EFFECTIVENESS; OBSERVATIONAL STUDIES; PHARMACOEPIDEMIOLOGY; PRESCRIPTION DATABASES; RECORD-LINKAGE; SAFETY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COOPERATIVE BEHAVIOR; DATA MINING; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FINLAND; GUIDELINE ADHERENCE; HUMANS; ICELAND; PHARMACOEPIDEMIOLOGY; PHARMACOVIGILANCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; SCANDINAVIA;

EID: 84880046715     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3457     Document Type: Review

References (60)

1. Strom B, Kimmel S, Hennessy S (Editors). Pharmacoepidemiology (5th edn), Wiley-Blackwell, 2012.
2. Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ 2009; 338: 804-6.
3. Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 2011; 10: 495-506.
4. Bergman U. Pharmacoepidemiological perspectives. J Clin Epidemiol 1992; 45: 313-7.
5. Black N Why we need observational studies to evaluate the effectiveness of healthcare. BMJ 1996; 312: 1215-8.
6. Wettermark B, Vlahovic-Palcevski V, Salvesen Blix H, Rønning M, Vander Stichele RH. Drug utilization research. Chapter in Hartzema AG, Tilson HH, Chan KA (eds). Pharmacoepidemiology and Therapeutic Risk Assessment. Harwey Whitney books: Cincinatti, USA 2008: 159-95.
7. Furu K, Wettermark B, Andersen M, Martikainen J, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010; 106: 86-94.
8. Furu K Establishment of the nationwide Norwegian Prescription Database (NorPD)-new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 2008; 18: 129-36.
9. Wettermark B, Hammar N, Fored M, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35.
10. Gaist D, Sørensen HT, Hallas J. The Danish prescription registers. Dan Med Bull 1997; 44: 445-8.
11. Hallas J Conducting pharmacoepidemiologic research in Denmark. Pharmacoepidemiol and Drug Safety 2001; 10: 619-23.
12. Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010; 2: 273-9.
13. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(7 Suppl): 38-41.
14. Klaukka T The Finnish database on drug utilization. Norwegian Journal of Epidemiology 2001; 11: 19-22.
15. Zoëga H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: a nationwide population-based study. Journal of child and adolescent psychpharmacology 2009; 9: 757-64.
16. Berg C, Furu K, Mahic M, et al. 2011 :2 Reseptregisteret 2006-2010/The Norwegian Prescription Database 2006-2010. Oslo 2011. Available from: http://www.fhi.no/dokumenter/ca931352dc.pdf (Assessed 27 Jan 2013).
17. Ludvigsson J, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659-67.
18. Swedish National Board of health and Welfare. Fyra år med läkemedelsregistret. [Publication celebrating the fourth anniversary of the Swedish Prescribed Drug register. National Board of Health and Welfare.] Edita Västra Aros: Västerås, Sweden, 2009. Socialstyrelsen, Stockholm 2009. ISBN: 978-91-86301-49-1.
19. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106, 000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008; 65: 653-60.
20. Olesen C, Thrane N, Henriksen TB, Ehrenstein V, Olsen J. Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19, 874 Danish women. Eur J Clin Pharmacol 2006; 62: 547-53.
21. Korhonen K, Dunder T, Klaukka T, Reijonen TM, Korppi M. Use of inhaled corticosteroids decreases hospital admissions for asthma in young children. World J Pediatr 2009; 5: 177-81.
22. Hansen ML, Gislason GH, Køber L, et al. Torp-Pedersen C. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol 2008; 65: 217-23.
23. Andersen SS, Hansen ML, Gislason GH, et al. Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction. Cardiology 2009; 112: 144-50.
24. Schneeweiss S Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007; 82: 143-56.
25. Clavenna A, Bonati M. Drug prescriptions to outpatient children: a review of the literature. Eur J Clin Pharmacol 2009; 65: 749-55.
26. Verhamme K, Sturkenboom M. Study designs in paediatric pharmacoepidemiology. Eur J Clin Pharmacol. 2011; 67(Suppl 1): 67-74.
27. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharm Ther 2012; 915: 796-801.
28. Crespin S, Bourrel R, Hurault-Delarue C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Drug prescribing before and during pregnancy in south west France: a retrolective study. Drug Saf 2011; 34: 595-604.
29. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004; 60: 659-66.
30. Irvine L, Flynn RW, Libby G, Crombie IK, Evans JM. Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland. Drug Saf 2010; 33: 593-604.
31. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 559-68.
32. Bjørn AM, Nørgaard M, Hundborg HH, Nohr EA, Ehrenstein V. Use of prescribed drugs among primiparous women: an 11-year population-based study in Denmark. Clin Epidemiol 2011; 3: 149-56.33.
33. Espnes MG, Bjørge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011; 20: 243-8.
34. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden-assessed by the prescribed drug register and the medical birth register. Clin Epidemiol 2011; 3: 43-50.
35. European Commission. Directorate General for Employment, Social Affairs and Inclusion and Eurostat. Demography report 2010-older, more numerous and diverse Europeans (20/05/2011) Available from: http://ec.europa.eu/social/main.jsp?catId=738&langId=en&pubId=5936&furtherPubs=yes (Assessed 27 Jan 2013)
36. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10: 430-9.
37. Jyrkkä J, Vartiainen L, Hartikainen S, Sulkava R, Enlund H. Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study. Eur J Clin Pharmacol 2006; 62: 151-8.
38. Haider SI, Johnell K, Thorslund M, Fastbom J. Analysis of the association between polypharmacy and socioeconomic position among elderly aged > or =77 years in Sweden. Clin Ther 2008; 30: 419-27.
39. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004; 329: 15-9.
40. Helldén A, Bergman U, von Euler M, Hentschke M, Odar-Cederlöf I, Öhlén G. Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department. A retrospective study. Drugs Aging 2009; 26: 595-606.
41. Spinewine A, Schmader KE, Barber N, et al. Prescribing in elderly people 1-appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370: 173-84.
42. Engel A, Siderius P. The consumption of drugs. Report on a study, 1966-1967. WHO Regional Office for Europe, Copenhagen 1968.
43. Bergman U, Elmes P, Halse M, et al. The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol 1975; 8: 83-9.
44. World Health Organization (WHO). Consumption of drugs: report on a symposium. Copenhagen, WHO regional Office for Europe, 1970 (EURO 3102).
45. Grimsson A, Idänpään Heikkilä J, Lunde PKM, Olafsson O, Westerholm B. The utilization of psychotopic drugs in Finland, Iceland, Norway and Sweden. Studies in drug utilization -Methods and Applications, Bergman U, Grimsson A, Wahba A, Westerholm B (eds). WHO Regional Publications. European Series No 8. World Health Organization. Regional Office for Europe: Copenhagen, 1979.
46. The EURO-MED-STAT Group. EURO-MED-STAT: monitoring expenditure and utilisation of medicinal products in the European Union countries. A public health approach. Eur J Pub Health 2003; 13: 95-100.
47. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H, ESAC Project Group. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004; 58: 419-28.
48. Walley T, Folino-Gallo P, Schwabe U, Van Ganse E, Stephens P, EuroMedStat Group. Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. Eur J Clin Pharmacol 2004; 60: 503-11.
49. Gülmez SE, Lignot-Maleyran S, de Vries CS, et al. Administrative complexities for a European observational study despite directives harmonising requirements. Pharmacoepidemiol Drug Saf 2012; 21: 851-6.
50. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344: d8012.
51. Wettermark B, Persson ME, Wilking N, et al. Gustafsson LL for the Regional Drug Expert Consortium. Forecasting drug use and expenditures in a metropolitan health region. BMC Health Service res 2010; 10: 12.
52. Martikainen JE, Enlund H. New chemical entities and their market penetration in Finland during the years 1996 through 2005. Clin Ther 2009; 31: 668-76.
53. Truffer CJ, Keehan S, Smith S, et al. Health spending projections through 2019: the recession's impact continues. Health Aff (Millwood) 2010; 29: 522-9.
54. Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures-2012. Am J Health Syst Pharm 2012; 69: e5-e21.
55. Larsen MD, Cars T, Hallas J. A minireview of the use of hospital-based databases in observational inpatient studies of drugs. Basic Clin Pharmacol Toxicol 2013; 112: 1318.
56. Norwegian Institute of Public Health. Gode helseregistre-bedre helse. Tiltak 42: Vurdere forprosjekt for å utrede fellesregister for legemidler, page 125. [Evaluation of a feasibility study for a common drug register.] Oslo 2009. Available from: http://www.fhi.no/dav/b948702828.pdf (Assessed 27 Jan 2013)
57. Swedish National Board of Health and Welfare. Stockholm 2012. Förstudie kring individdata för rekvisitionsläkemedel. [A feasibility study on patient identity data for drugs administered in the hospital setting.] Available from: http://www.socialstyrelsen.se/publikationer2012/2012-4-21 (Assessed 27 Jan 2013)
58. Finnish Statistics on Medicines. Finnish Medicines Agency Fimea and Social Insurance Institution. Helsinki 2011 Available from: http://www.kela.fi/in/internet/english.nsf/NET/140803133205MP?OpenDocument (Assessed 27 Jan 2013)
59. Swedish National Board of Health and Welfare. Läkemedel-statistik för år 2011. Socialstyrelsen, Stockholm 2012 [Drug statistics for 2011] Available from: http://www.socialstyrelsen.se/publikationer2012/2012-3-28 (Assessed 27 Jan 2013)
60. Danish Health and Medicines Authority. Five-year statistics on drug consumption 2006-2010. Copenhagen, 2011 http://laegemiddelstyrelsen.dk/en/topics/statistics, -prices-and-reimbursement/statistics-and-analyses/news-about-statistics-og-analyses/five-year-statistics-on-drug-consumption-2006-2010 (Assessed 27 Jan 2013)